8-K: Hologic Announces Q2 Fiscal 2025 Results: Revenue Slightly Exceeds Guidance, EPS at High End

Hologic reports Q2 fiscal 2025 revenue of $1,005.3 million, slightly exceeding guidance, with non-GAAP EPS of $1.03 at the high end of guidance, while maintaining annual revenue guidance but lowering GAAP and non-GAAP EPS guidance.

Summary

• Hologic announced its financial results for the second quarter of fiscal year 2025, ended March 29, 2025.
• Revenue reached $1,005.3 million, a decrease of 1.2% year-over-year, but slightly exceeding the guidance range of $995 to $1,005 million.
• In constant currency, revenue decreased by 0.5%.
• GAAP diluted EPS was a loss of ($0.08), compared to $0.72 in the prior year, due to non-cash impairment charges of $220.9 million.
• Non-GAAP EPS was $1.03, flat compared to the prior year and at the high end of the guidance range of $1.00 to $1.03.
• Diagnostics revenue increased by 0.8% to $453.6 million, or 1.5% in constant currency.
• Excluding COVID-19 revenue, organic diagnostics sales grew 4.5%, or 5.2% on a constant currency basis.
• Breast Health revenue decreased by 7.4% to $356.2 million, or 6.9% in constant currency.
• Surgical revenue grew by 4.2% to $162.5 million, or 5.1% in constant currency.
• The company repurchased 3.0 million shares for $200 million during the quarter.
• Full-year revenue guidance is maintained at $4,050 $4,100 million, but non-GAAP EPS guidance is lowered to $4.15 $4.25 due to tariffs and geopolitical conditions.
• Third-quarter revenue is expected to be $1,000 $1,010 million, with non-GAAP EPS of $1.04 $1.07.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue slightly exceeded guidance and non-GAAP EPS was strong, there were declines in overall revenue and GAAP EPS due to impairment charges, and the full-year EPS guidance was lowered.

Positives

• Revenue slightly exceeded guidance at $1,005.3 million.
• Non-GAAP EPS was at the high end of guidance at $1.03.
• Diagnostics revenue showed growth, increasing by 0.8% (1.5% in constant currency).
• Molecular diagnostics revenue increased by 1.0% (1.7% in constant currency).
• Surgical revenue experienced growth of 4.2% (5.1% in constant currency).
• Skeletal health revenue increased 21.8%, or 22.9% in constant currency.
• The company repurchased 3.0 million shares for $200 million.
• The company ended the quarter with cash and cash equivalents of $1.43 billion and an adjusted net leverage ratio (net debt over adjusted EBITDA) of 0.8 times.
• Adjusted Return on Invested Capital (ROIC) was 13.7%, an increase of 30 basis points compared to the prior year period.

Negatives

• Overall revenue decreased by 1.2% compared to the prior year.
• GAAP diluted EPS was a loss of ($0.08) due to significant impairment charges.
• Breast Health revenue decreased by 7.4% (6.9% in constant currency).
• The company lowered its full-year non-GAAP EPS guidance due to tariffs and geopolitical conditions.
• GAAP gross margin of 37.5% decreased (1,580) basis points primarily due to impairment charges on intangible assets.
• GAAP operating margin of (0.7%) decreased (2,140) basis points primarily due to impairment charges on intangible assets.
• GAAP net income (loss) of ($17.4) million decreased (110.2%), while non-GAAP net income of $232.9 million decreased (4.6%).
• Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) were $325.8 million, a decrease of (2.9%).

Risks

• The company faces risks related to the development of new competitive technologies and products.
• Inaccurate predictions of product demand could adversely affect the company.
• Consolidation in the healthcare industry poses a risk.
• The company's ability to execute and integrate acquisitions successfully is a risk.
• Coverage and reimbursement decisions by third-party payors could impact results.
• Cost containment efforts and healthcare reform legislation present uncertainty.
• Regulatory approvals and compliance with evolving standards are ongoing risks.
• Product defects or errors could negatively impact performance.
• Legal proceedings and compliance risks could lead to negative impacts.
• Climate change and other ESG-related matters pose potential risks.
• Future tax legislation could have an impact.
• Global challenges, including macroeconomic uncertainties, wars, and recession concerns, could affect the business.
• Worldwide political and social uncertainty could impact trade regulations and costs.
• Cybersecurity threats and computer crime are ongoing risks.
• Supply chain constraints and cost inflation could affect the company.
• Interruptions at manufacturing facilities or failure of sole-source suppliers could disrupt operations.
• The company's ability to consolidate operations and achieve cost synergies is a risk.
• The company's ability to meet production and delivery schedules is a risk.
• Future public health pandemics or crises could have an impact.
• The company's ability to manage organizational and strategic changes is a risk.
• The company's ability to protect its intellectual property rights is a risk.
• Interest rate and foreign currency exchange fluctuations could impact results.
• Compliance with debt covenants is a risk.
• The company's liquidity and capital resources are subject to risk.

Future Outlook

Hologic maintains its full-year revenue guidance of $4,050 $4,100 million but lowers its non-GAAP EPS guidance to $4.15 $4.25 due to tariffs and geopolitical conditions; Q3 2025 revenue is expected to be $1,000 $1,010 million, with non-GAAP EPS of $1.04 $1.07.

Management Comments

• Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer, stated, 'We delivered on our financial commitments in the second quarter.'
• He added that both revenue and non-GAAP EPS finished at the high ends of their guidance ranges, driven by diagnostics and skeletal businesses, strong profitability, share buybacks, and a slightly lower tax rate.
• Karleen Oberton, Hologic's Chief Financial Officer, mentioned that they are maintaining full-year revenue guidance but lowering non-GAAP EPS guidance slightly based on tariffs and geopolitical conditions.

Industry Context

Hologic's results reflect the ongoing trends in the medical technology industry, including the shift in demand for COVID-19 related products, the importance of organic growth in core businesses, and the impact of acquisitions on overall performance. The company's focus on women's health aligns with the increasing emphasis on preventative care and early detection in healthcare.

Comparison to Industry Standards

• Hologic's gross margin of 61.1% is comparable to other medical device companies such as Intuitive Surgical (around 70%) and Stryker (around 65%).
• The company's revenue growth of -1.2% is lower than some of its faster-growing peers like Exact Sciences, which has been experiencing double-digit growth.
• Hologic's adjusted net leverage ratio of 0.8 times is relatively conservative compared to some companies in the industry that carry higher debt loads.
• The company's ROIC of 13.7% is a good result compared to the industry average.

Stakeholder Impact

• Shareholders may be concerned about the decrease in GAAP EPS and the lowered full-year EPS guidance.
• Employees may be affected by restructuring and integration efforts.
• Customers will likely see continued focus on women's health products and services.
• Suppliers may be impacted by supply chain constraints and cost inflation.
• Creditors should be reassured by the company's low net leverage ratio.

Key Dates

Keywords

financial results, Hologic, revenue, EPS, diagnostics, breast health, surgical, guidance, Q2 2025, medical technology